Antileukotriene treatment in children with asthma--new patents.
Leukotrienes, and especially cysteinyl leukotrienes have been shown to be involved in many processes that play a role in asthma pathophysiology: eosinophil recruitment, the most characteristic processes of asthma pathogenesis, increased mucosal secretion, which impairs the normal process of airway clearance and favors the development of mucus plugs, mucosal edema, caused by increased vascular permeability and bronchoconstriction, leading to smooth muscle hypertrophy. Latest progress in the understanding of chronic asthma pathology events underline the leukotriene synthesis pathway enzymes and different leukotriene receptors as potential targets of asthma treatment in children. Agents inhibiting the production of leukotrienes or agents antagonising their receptor's action, attract attention. Studies on molecular mechanisms of leukotrienes action have led to the development and patents of potential drugs including new 5-lipoxygenase inhibitors, 5-lipoxygenase-activating protein (FLAP) inhibitors, leukotriene B4 receptor antagonists, or nanoparticulate leukotriene receptor antagonist formulations.
Stelmach
Iwona
I
Department of Pediatrics and Allergy, N Copernicus Hospital, Lodz, Poland. alergol@kopernik.lodz.pl
Grzelewski
Tomasz
T
D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D002648:Child; D003545:Cysteine / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D020024:Leukotriene Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D015289:Leukotrienes / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D010330:Patents as Topic; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors
D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; D018927:Anti-Asthmatic Agents; D002352:Carrier Proteins; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D018102:Receptors, Leukotriene B4; C112381:cysteinyl-leukotriene; D003545:Cysteine